KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Current Deferred Revenue (2019 - 2025)

Esperion Therapeutics (ESPR) has disclosed Current Deferred Revenue for 7 consecutive years, with $34.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Current Deferred Revenue rose 304.75% year-over-year to $34.5 million, compared with a TTM value of $34.5 million through Dec 2025, up 304.75%, and an annual FY2025 reading of $34.5 million, up 304.75% over the prior year.
  • Current Deferred Revenue was $34.5 million for Q4 2025 at Esperion Therapeutics, up from $30.7 million in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $34.5 million in Q4 2025 and bottomed at $2.5 million in Q1 2021.
  • Average Current Deferred Revenue over 5 years is $13.5 million, with a median of $10.3 million recorded in 2023.
  • The sharpest move saw Current Deferred Revenue soared 624.32% in 2023, then tumbled 84.52% in 2025.
  • Year by year, Current Deferred Revenue stood at $5.7 million in 2021, then tumbled by 38.29% to $3.5 million in 2022, then skyrocketed by 624.32% to $25.4 million in 2023, then crashed by 66.47% to $8.5 million in 2024, then skyrocketed by 304.75% to $34.5 million in 2025.
  • Business Quant data shows Current Deferred Revenue for ESPR at $34.5 million in Q4 2025, $30.7 million in Q3 2025, and $22.3 million in Q2 2025.